43例乳腺导管内癌伴微浸润的ER-β和Her-2表达与临床病理特征  

Relationship between the expression of ER-β and Her-2 in breast ductal carcinoma in situ with microinvasion and its clinical pathological features

作　　者：鲁祥石[1] 何川[1] 李万喜[1] 徐宏刚[1] 李志高[1] 庞达[1] 

机构地区：[1]哈尔滨医科大学第三临床医学院乳腺外科,黑龙江哈尔滨150081

出　　处：《哈尔滨医科大学学报》2009年第6期590-592,共3页Journal of Harbin Medical University

基　　金：黑龙江省卫生厅资助项目(2007-389)

摘　　要：目的研究乳腺导管内癌伴微浸润(ductal carcinoma in situ with microinvasion,DCIS-MI)患者的病理与临床特征。方法对本院2002年1月至2007年1月收治的43例Ⅰ、Ⅱ型DCIS-MI患者的临床资料进行回顾性对比研究,利用免疫组织化学方法进行ER-β及Her-2染色。结果①ER-β、Her-2阳性率分别为69.76%、25.57%;②病理分型DCIS-MIⅠ与DCIS-MIⅡ组,ER-β与Her-2表达具有统计学差异;肿瘤大小与ER-β、Her-2表达呈正相关;淋巴结转移数量增多,Her-2表达增高。Her-2过表达与乳腺癌临床TNM分期显著相关(P<0.001)。结论乳腺癌ER-β、Her-2表达与病理类型、肿瘤大小、淋巴结转移数目及临床分期密切相关。ER-β阳性可认为是乳腺癌预后良好的指标,而Her-2的过表达则提示预后不良。Objective To study the clinical and pathological characteristics of breast ductal carcinoma in situ with microinvasion （DCIS-MI）. Methods From January 2002 to January 2007,a total of 43 patients with DCIS-MI patients were retrospectively studied by calculating the protein expression of ER-β and Her-2. Results The positive expression of ER-β and Her-2 were 69. 76% and 25. 57% respectively. Pathology varied between DCIS-MI typeⅠand typeⅡ. The size of tumor was positive associated with ER-β and Her-2. It showed that the Her-2 expression was up-regulated with a increased size of tumor and number of lymphonode in metastasis cases. Conclusion ER-β and Her-2 are associated with pathologi- cal type, tumor size, number of lymphonode and clinical stage in breast cancer tissue. ER-β positive can be considered as a good indicator of prognosis but Her-2 is opposite.

关 键 词：乳腺肿瘤 肿瘤浸润 导管内癌微浸润 雌激素Β受体 表皮生长因子受体2型 

分 类 号：R737.9[医药卫生—肿瘤]